Skip to content
Friday 7 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,867.89
-0.19%
DAX
26,140.13
0.00%
CAC 40
8,699.71
0.00%
STOXX 50
6,502.56
0.00%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE

Drugs

  • Sweeping job cuts at GSK to fund £400m Cambridge campus

    Pharma

    GSK is poised to slash its back office headcount to help fund a £400m mega-campus in Cambridge, in a move it hopes will bolster its drugs pipeline anFd stave off a looming patent cliff-edge. In his first major update as chief executive, Luke Miels unveiled plans to find £1.9bn of savings over the next three [...]

    Modern GSK Cambridge campus buildings with sky bridge, green spaces, and people walking and cycling.
  • City trader: ‘My coke dealer came to the Canary Wharf office every day at 9am’

    Video

    A former star City trader has opened up about a devastating cocaine addiction that devoured hundreds of thousands of pounds – and nearly killed him. Kent Bray talks to Morning Wire Editor Christian May about his high-flying career at Citibank and his rock-bottom drug addiction. In a remarkably candid interview Bray, who mentored YouTube activist [...]

    Skyline of Canada financial district with modern skyscrapers and historic landmarks under a clear blue sky
  • GSK strikes deal to cut drug prices with US government

    GSK has struck a voluntary agreement with the US government to lower the cost of prescription medicines and expand access to treatments for millions of Americans. The move comes as pressure mounts on global drugmakers over pricing, tariffs, and domestic investment. The London-listed pharma giant said the deal covers medicines used by over 40m US [...]

    Hikma produces generic drugs
  • Trump slaps 100 per cent tariff on imported drugs

    September 26, 2025

    US President Donald Trump announced a new round of tariffs on Thursday evening, with the pharmaceutical industry expected to be the hardest hit. Trump revealed that the US will impose a 100 per cent tariff on imported branded drugs, a 25 per cent tariff on all heavy-duty truck imports, a 50 per cent tariff on [...]

  • Glastonbury weekend: drugs testing can save lives this festival season

    June 26, 2025

    No matter what organisers do, there will always be drugs at festivals like Glastonbury, so why not make sure they are as safe as possible? Asks Sacha Lord This weekend will see the doyenne of festivals, Glastonbury, will fire the starting gun on the summer party season. At every single major festival in the UK [...]

  • The Debate: Should the UK decriminalise cannabis?

    June 4, 2025

    Sadiq Khan says yes, but is the UK really ready for looser rules around cannabis? We get two experts to argue for and against.

  • Sadiq Khan backs calls to decriminalise cannabis possession

    May 28, 2025

    A report commissioned by Sadiq Khan has called for decriminalising the possession of cannabis in small quantities, in a major policy pivot for City Hall. The London Drugs Commission, which was set up by the Mayor of London two years ago, argues that while the production and supply of cannabis should continue to “be policed [...]

  • GSK and Astrazeneca shares slump as Trump vows drug price cut

    May 12, 2025

    GSK and Astrazeneca shares fall as Trump announces drug price cuts in a new executive order.

  • Astrazeneca chief blasts Europe for ‘putting citizens’ health at risk’

    April 23, 2025

    Europe is putting its “ability to protect the health of its own people at risk” by not investing enough, the chief executive of FTSE 100 giant Astrazeneca has warned. Pascal Soriot added that the continent is “falling behind” in attracting R&D and manufacturing investment and needs to “invest more in what really matters to it”. [...]

  • GSK shares rise after £1.7bn Zantac settlement

    October 10, 2024

    GSK shares have spiked today after the pharmaceutical giant agreed to pay as much as $2.2bn (£1.68bn) to settle lawsuits alleging one of its heartburn drugs had caused cancer. The discontinued version of the drug, Zantac, had triggered 80,000 lawsuits from 10 different law firms in the US and has hung over the FTSE 100 [...]

Posts pagination

  • Page 1
  • Page 2
  • Next

Trending Articles

  • Rupert Lowe axes pensions triple lock and pledges tax cuts in economic plan

  • Revolut founder’s wealth set to balloon amid talks of share award at $500bn valuation

  • As it happened: Stocks rise as oil fluctuates after Red Sea attack; US-Iran deal ‘being circulated’

  • Liverpool owners tipped to sell – but not to Amazon boss Bezos – by former CEO

  • WPP slashes jobs as revenue continues to fall

MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook